UnitedHealth Group has traded at a significant premium to its peers for years, driven by its diversified Optum services and stable Medicare business. Over the past 12 months, however, UNH shares have underperformed large-cap health insurers by approximately 8%, prompting investors to question the sustainability of its valuation. Despite a one-year high of $606.36 and a low of $234.60, consensus forecasts now peg UNH’s fair value closer to $377, down from analyst targets as high as $418 earlier in the year. The stock’s current price-to-earnings ratio of 21.8 and PEG of 1.35 remain above industry averages, even as revenue growth has cooled to 12.3% year-over-year in the latest quarter.

Form 13F filings reveal that Lee Financial Co opened a new position of 3,390 shares in Q3, deploying approximately $1.17 million, while Brighton Jones LLC more than doubled its stake to 44,249 shares, investing an additional $22.38 million. Revolve Wealth Partners added 2,324 shares for a 137.1% increase, now holding 4,019 shares valued at $2.03 million. These moves contrast with Thrivent Financial’s 7.0% reduction of 34,694 shares in the same period. Overall, hedge funds and other institutions maintain 87.9% ownership, indicating broad long-term conviction despite recent price softness.

Equity research has been mixed: Jefferies cut its target from $418 to $340 but kept a Buy rating, while Oppenheimer lowered its objective from $415 to $385 and retained an Outperform call. TD Cowen and KeyCorp reaffirmed Hold and Overweight stances, respectively. UNH’s latest earnings beat consensus by $0.02, reporting $2.11 EPS on $113.22 billion in revenue. Management set FY26 EPS guidance at 17.75, below the Street’s 29.54 forecast, reflecting anticipated margin pressure. The company maintains a quarterly dividend of $2.21, yielding 3.1% with a payout ratio of 67.0%, and carries a debt-to-equity ratio of 0.72, underscoring a solid balance sheet in support of ongoing capital returns.